Skip to main content
Download PDF

Effect of disease duration on the association between C-reactive protein-albumin ratio and endoscopic activity in ulcerative colitis

BMC Gastroenterology volume 22, Article number: 39 (2022) Cite this article

Abstract

Background

A simple serum biomarker for clinical outcome in patients with ulcerative colitis (UC) remains an unmet need. Some studies have shown an association between C-reactive protein (CRP)-albumin ratio (CAR) and prognosis in patients with inflammatory bowel disease (IBD), but evidence regarding the association between CAR and UC remains limited. We evaluated the association between CAR and clinical outcome in Japanese patients with UC.

Methods

Subjects were 273 Japanese patients with UC. Clinical remission was defined as absence of both abnormally high stool frequency (< 3 per day) and rectal bleeding. Mucosal healing (MH) was defined as Mayo endoscopic subscore (MES) 0. Moderate to severe endoscopic activity was defined as MES 2–3. Subjects were divided according to CAR into tertiles (low, moderate, and high).

Results

The proportions of patients with clinical remission, MH, and moderate to severe endoscopic activity were 57.9%, 26.0%, and 37.0%, respectively. High CAR was significantly positively associated with moderate to severe endoscopic activity but not MH or clinical remission after adjustment (adjusted odds ratio [OR] 2.18 [95% confidence interval (CI) (1.11–4.35)], p for trend 0.023), but only in patients with long disease duration (> 7 years) (adjusted OR 2.95 [95% CI (1.06–8.79)], p for trend 0.023). CAR was not associated with clinical remission or MH.

Conclusions

CAR may be significantly positively associated with moderate to severe endoscopic activity but not clinical remission or MH in Japanese patients with UC. In patients with long UC duration, CAR might be a useful serum marker for disease activity.

Peer Review reports

Background

Ulcerative colitis (UC), one of the inflammatory bowel diseases (IBD), is affecting growing numbers of patients worldwide [1]. While the clinical course of UC is characterized by repeated relapses and remissions [2], the majority of patients tend to have mild to moderate disease activity [3]. Yet 10–20% of patients have acute severe UC that persists after onset, and severe UC flare-up is associated with a 1% mortality rate [3]. The association between anti-tumor necrosis factor (TNF) α monoclonal antibody treatment and long-term colectomy rate among UC patients is still unclear [4].　Early detection of relapses, flares, changes in disease activity, and responses to treatments is key to recommending appropriate additional treatments, and thus to preventing complications and improving prognosis and quality of life [5, 6]. Despite many investigations into possible associations between various biomarkers and UC disease activity, the available serum biomarkers still have lower sensitivity and specificity for disease activity than fecal markers[7]. Accordingly, colonoscopy remains the gold standard for assessing UC disease activity. A serum biomarker with comparable sensitivity and specificity would allow us to assess disease activity more easily, more repeatably, and less invasively than we currently can.

Recently, some studies have reported an association between the C-reactive protein (CRP)-to-albumin ratio (CAR), a useful serum marker for several other diseases [8,9,10,11,12], and UC [13,14,15,16]. Evidence regarding the association between CAR and clinical outcomes in UC remains scarce, however. Here, we aimed to evaluate the association between CAR and clinical outcomes in UC as assessed in terms of clinical remission, mucosal healing and endoscopic disease severity and to explore whether duration of disease affects that association in Japanese patients with UC.

Materials and methods

Study population

The subjects of this study were patients with ulcerative colitis attending or hospitalized at the Department of Gastroenterology and Metabolism, Ehime University Graduate School of Medicine or affiliated hospitals in Ehime Prefecture from 2015 to 2019. All patients whose attending physicians were expected to be able to answer the self-administered questionnaire were included in the study. Most UC cases were diagnosed on the basis of endoscopic findings, which were additionally confirmed by radiographic and histological findings.

This study was planned in accordance with the Declaration of Helsinki, and the study protocol was reviewed and approved by the Institutional Review Board of Ehime University (Institutional approval number #1505011). Written informed consent was obtained from all enrolled patients by well-trained staff. The final analysis sample for this analysis consisted of 273 patients out of 387 UC patients enrolled in this cohort study, excluding 114 patients with incomplete data.

Variables analysed

To obtain information on body mass index, endoscopic findings, disease extent, clinical remission, and the use of medication for UC, we examined patients’ medical records. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. Blood samples were taken in the morning after overnight fasting. Blood examination was performed when a colonoscopy was booked or when the colonoscopy was performed; there may have been an interval of up to two months between the blood examination and the colonoscopy.

Assessment of clinical remission, endoscopic activity and MH

The definition of clinical remission was based on no rectal bleeding and no abnormally high stool frequency (cutoff frequency: three times per day). MH and moderate to severe endoscopic activity were assessed using the Mayo endoscopic subscore (MES) [17]. In this study, the definition of MH was MES 0; moderate and severe activity were defined as MES 2 and 3, respectively. Certified gastrointestinal endoscopists reported their endoscopic findings, and one endoscopist, who was blinded to the CAR level, was responsible for interpretation of the endoscopic findings.

Statistical analysis

CARs were divided into categories by thirds based on the distribution of all subjects. These tertiles were used to group subjects into three categories: 1) low CAR, ≤ 0.012 (reference); 2) moderate CAR, 0.012–0.038; and 3) high CAR, ≥ 0.038. Multiple comparisons were analyzed using the Steel–Dwass test. The crude odds ratios (ORs) and their 95% confidence intervals (CIs) for clinical remission, MH, and moderate to severe endoscopic activity in relation to CAR were analyzed using logistic regression analysis. Age, gender, BMI, prednisolone use, anti-TNFα monoclonal antibody preparation, extent of disease (proctitis/non-proctitis), and disease duration were selected a priori as potential confounders. Multiple logistic regression analyses were used to adjust for potential confounders. Most of statistical analyses were performed using SAS software package version 9.4 (SAS Institute Inc., Cary, NC, USA). A receiver operating characteristic (ROC) curve, cutoff value of CAR (Youden’s index), sensitivity, and specificity were analyzed using JMP 14.2 software (SAS Institute Inc.).

Results

Table 1 shows the characteristics of this cohort. The rates of clinical remission, MH, and moderate to severe endoscopic activity were 57.9%, 26.0%, and 37.0%, respectively. Prednisolone and TNF-α monoclonal antibody preparations were used by 21.6% and 6.2% of patients, respectively. Mean serum albumin, median CRP, and median CAR were 4.218 g/dl, 0.099 mg/dl and 0.022, respectively. The CAR value in MES 2 or 3 was significantly higher than that in MES 0 (Fig. 1). There was no significant difference in CAR values between MES2 and MES3.

Table 1 Clinical characteristics of 273 study participants
Full size table
Fig. 1
figure 1

CAR value by Mayo score

Full size image

Table 2 shows the crude and adjusted ORs and 95%CIs for clinical remission, MH, and moderate to severe endoscopic activity in relation to CAR. High CAR was inversely associated with MH (crude OR 0.48 [95%CI: 0.23–0.97]); after adjustment for age, sex, BMI, prednisolone use, anti-TNFα monoclonal antibody preparation, disease extent (proctitis/non-proctitis), and disease duration, however, the inverse association between CAR and MH disappeared. A positive association between CAR and moderate to severe endoscopic activity (MES 2 or 3) was found (crude OR 2.39 [95%CI: 1.31–4.43]); after adjustment, this association was still significant (adjusted OR 2.18 [95%CI: 1.11–4.35], p for trend = 0.023).

Table 2 Crude and adjusted odds ratios and 95% confidence intervals for associations between clinical outcomes and CAR
Full size table

The association between CAR and clinical outcomes in patient groups classified according to disease duration is shown in Table 3. In the short-duration group (≤ 7 years), high CAR was positively associated with moderate to severe endoscopic activity (crude OR 2.41 [95% CI: 1.08–5.51]; after adjustment, however, this association completely disappeared. In the long-duration group (> 7 years), in contrast, high CAR was independently associated with moderate to severe endoscopic activity even after adjustment (adjusted OR 2.95 [95% CI: 1.06–8.79], p for trend = 0.032). CAR was not associated with clinical remission or MH regardless of disease duration.

Table 3 Crude and adjusted odds ratios and 95% confidence intervals for associations between clinical outcomes and CAR according to duration of UC. Short duration (≤ 7 years) (n = 143)
Full size table

The predictive value of CAR for moderate to severe disease activity was investigated through ROC curve analysis (Fig. 2). The area under the curve was 0.633. The sensitivity and specificity for moderate to severe endoscopic activity (with a CAR cut-off value of 0.030) were 54.8% and 70.8%, respectively. In sensitive analysis, the CAR value in pancolitis (0.024 ± 0.120) was higher than that in proctitis (0.014 ± 0.020). Serum albumin (mean ± SD) and CRP (median ± IQR) value in low CAR, moderate CAR, and high CAR were 4.32 ± 0.34 g/dl, 0.03 ± 0.02 mg/dl; 4.29 ± 0.36 g/dl, 0.10 ± 0.03 mg/dl; and 4.03 ± 0.52 g/dl, 0.45 ± 0.72 mg/dl, respectively.

Fig. 2
figure 2

Receiver operating characteristic curve of CAR as a marker for MES 2 and 3. The receiver operating characteristic (ROC) curve of CAR as a marker for moderate-severe stage had an area under the curve of 0.633. When the cut-off CAR level was set to 0.030, the sensitivity and specificity for MH were 54.8% and 70.8%, respectively

Full size image

Discussion

The present study demonstrated that CAR was independently positively associated with moderate to severe endoscopic activity in patients with UC. No association was found between CAR and other clinical outcomes including MH and clinical remission.

Several previous studies have explored the association between CAR and clinical outcomes in patients with UC. A Turkish study of 149 patients with UC found a relationship between CAR and clinical disease activity whereby CAR value was associated with the difference between moderate and severe disease activity [13].In a Chinese study of 876 patients with IBD, including 275 patients with UC, CAR was highly useful for identifying patients with active-stage IBD [14]. In an Irish study of 124 patients with acute severe UC, CAR was significantly higher in steroid-refractory patients than in steroid-responsive patients [15]. In an Australian retrospective study of steroid-refractory UC patients, CAR was positively associated with colectomy after infliximab [16]. Taking these results together, CAR is positively associated with clinical activity, endoscopic activity, and poor response to medication in UC patients. The results of the present study are consistent with these previous findings indicating an association between CAR and clinical outcomes.

The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) study recommended treat-to-target strategies for patients with IBD [18, 19]. While maintaining MH remains the larger goal, the normalization of serum and fecal biomarkers has been identified as a short-term target. The development of an easy, rapid, repeatable, and affordable serum marker for MH is one of the unmet needs related to maintaining MH in the clinical setting. Several novel biomarkers for MH have recently been reported, including the CAR as well as serum globulin, serum indirect bilirubin, neutrophil/lymphocyte ratio, albumin/platelet ratio, and platelet/lymphocyte ratio [20,21,22,23]. Our results indicate that CAR should be used as serum marker for disease activity and poor response to treatment but not for MH.

Only a few studies have explored the influence of disease duration on biomarker accuracy in patients with IBD. In patients with Crohn’s disease, disease duration did not affect the utility of fecal calprotectin as a biomarker [24]. In patients with UC, on the other hand, the immunochemical fecal occult blood test as a biomarker for MH is more accurate in patients with disease duration < 4 years [25]. Similarly, serum albumin was found to be a useful marker for MH in patients with shorter UC duration but not in those with longer UC duration [26]. In the present study, CAR was associated with disease activity only in UC patients with longer disease duration but not in those with shorter disease duration. It remains uncertain why disease duration affects the association between CAR and disease activity in patients with UC. Further research regarding the association between disease duration and serum biomarker accuracy in patients with UC is warranted.

Although the mechanism underlying the link between CAR and disease activity remains unclear, there are several biologically plausible possibilities. Both CRP and albumin are widely used as acute inflammatory markers in clinical settings, and albumin is also used as a marker of malnutrition. During inflammation, cytokines such as TNF α and IL-6 may suppress albumin synthesis in the liver [27]. Chronic and severe inflammation leads to hypercytokinemia, which can lead to malnutrition [28]. It is possible that CAR is related to severe and/or chronic inflammation but not to mild inflammation. This would explain why CAR is associated with disease activity only in patients with long disease duration.

There are several limitations to this study. First of all, it was a cross-sectional study. Therefore, causality between CAR and MH needs to be confirmed by conducting longitudinal and interventional studies. Secondly, many of the patients in this cohort were on long-term treatment and had high clinical remission. Long-term treatment might affect the association between CAR and endoscopic activity. Third, fecal calprotectin is recognized as a reliable marker of MH, however, the calprotectin data was missing in this cohort. Fourth, other clinical scores, including the Clinical Activity Index, were missing in this cohort. Finally, selection bias may have affected the results. The characteristics of this cohort might be different those of Japanese ulcerative colitis. However, the sex ratio, median age (years), and frequency of anti-TNFα monoclonal antibody use (63.9%, 44.0, and 9.0%, respectively) in the Japanese national study were similar to those in this study (57.9%, 48.0, and 6.2%, respectively) [29].

Conclusions

In Japanese patients with UC, CAR might be significantly positively associated with endoscopic activity. No association between CAR and MH was found in this cohort. In clinical settings, CAR can be used as a marker of disease activity but should not be used as a marker of remission, including MH, in patients with long UC duration.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

Alb:

Albumin

BMI:

Body mass index

CAR:

C-reactive protein/albumin ratio

CRP:

C-reactive protein

MES:

Mayo endoscopic subscore

MH:

Mucosal healing

ROC:

Receiver operating characteristic

STRIDE:

Selecting Therapeutic Targets in Inflammatory Bowel Disease

TNF:

Tumor necrosis factor

UC:

Ulcerative colitis

References

  1. Ng SC, Shin HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390(10114):2769–78. https://doi.org/10.1016/S0140-6736(17)32448-0.

    Article  Google Scholar 

  2. Langholz E, Munkholm P, Davidsen M, et al. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994;107(1):3–11. https://doi.org/10.1016/0016-5085(94)90054-x.

    Article  CAS  PubMed  Google Scholar 

  3. Dinesen LC, Walsh AJ, Protic MN, et al. The pattern and outcome of acute severe colitis. J Crohns Colitis. 2010;4(4):431–7. https://doi.org/10.1016/j.crohns.2010.02.001.

    Article  PubMed  Google Scholar 

  4. Gallo G, Kotze PG, Spinelli A. Surgery in ulcerative colitis: when? how? Best Practice Res Clin Gastroenterol. 2018;32–33:71–8. https://doi.org/10.1016/j.bpg.2018.05.017.

    Article  Google Scholar 

  5. Magro F, Gionchetti P, Eliakim P, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1:Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11(6):649–70. https://doi.org/10.1093/ecco-jcc/jjx008.

    Article  PubMed  Google Scholar 

  6. Gomollón F, Dignass A, Annese V, et al. Third European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2016;11(1):3–25. https://doi.org/10.1093/ecco-jcc/jjw168.

    Article  PubMed  Google Scholar 

  7. Krzystek-Korpacka M, Kempiński R, et al. Biochemical biomarkers of mucosal healing for inflammatory bowel disease in adults. Diagnostics (Basel). 2020;10(6):367. https://doi.org/10.3390/diagnostics10060367.

    Article  CAS  Google Scholar 

  8. Wu L, Tan W, Chen L, et al. Clinicopathologic and prognostic significance of C-reactive protein/albumin ratio in patients with solid tumors: an updated systemic review and meta-analysis. Oncotarget. 2018;9(17):13934–47. https://doi.org/10.18632/oncotarget.24172.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Akkececi NS, Cetin GY, Gogebakan H, et al. The C-reactive protein/albumin ratio and complete blood count parameters as indicators of disease activity in patients with Takayasu arteritis. Med Sc Monit. 2019;25:1401–9. https://doi.org/10.12659/MSM.912495.

    Article  CAS  Google Scholar 

  10. Kaplan M, Ates I, Akpinar MY, et al. Predictive value of C-reactive protein/albumin ratio in acute pancreatitis. Hepatobiliary Pancreat Dis Int. 2017;16(4):424–30. https://doi.org/10.1016/S1499-3872(17)60007-9.

    Article  PubMed  Google Scholar 

  11. Ranzani OT, Zampieri FG, Forte DN, et al. C-reactive protein/albumin ratio predicts 90-day mortality of septic patients. PLoS ONE. 2013;8(3): e59321. https://doi.org/10.1371/journal.pone.0059321.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Bender M, Haferkorn K, Friedrich M, et al. Impact of early C-reactive protein/albumin ratio on intra-hospital mortality among patients with spontaneous intracerebral hemorrhage. J Clin Med. 2020;9(4):1236. https://doi.org/10.3390/jcm9041236.

    Article  CAS  PubMed Central  Google Scholar 

  13. Sayar S, Kurbuz K, Kahraman R, et al. A practical marker to determining acute severe ulcerative colitis: CRP/albumin ratio. North Clin Istanb. 2020;7(1):49–55. https://doi.org/10.14744/nci.2018.78800.

    Article  PubMed  Google Scholar 

  14. Chen YH, Wang L, Feng SY, et al. The relationship between C-reactive protein/albumin ratio and disease activity in patients with inflammatory bowel disease. Gastroenterol Res Pract. 2020;2020:3467419. https://doi.org/10.1155/2020/3467419.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Gibson DJ, Hartery K, Doherty J, et al. CRP/albumin ratio: an early predictor of steroid responsiveness in acute severe ulcerative colitis. J Clin Gastroenterol. 2018;52(6):e48-52. https://doi.org/10.1097/MCG.0000000000000884.

    Article  CAS  PubMed  Google Scholar 

  16. Con D, Andrew B, Nocolaides S, et al. Biomarker dynamics during infliximab salvage for acute severe ulcerative colitis: C-reactive protein (CRP)-lymphocyte ratio and CRP-albumin ratio are useful in predicting colectomy. Intest Res. 2021. https://doi.org/10.5217/ir.2020.00146.

    Article  PubMed  Google Scholar 

  17. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med. 1987;317(26):1625–9. https://doi.org/10.1056/NEJM198712243172603.

    Article  CAS  PubMed  Google Scholar 

  18. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570–83. https://doi.org/10.1053/j.gastro.2020.12.031.

    Article  CAS  PubMed  Google Scholar 

  19. Colombel JF, D’haens G, Lee WJ, et al. Outcomes and strategies to support a treat-to-target approach in inflammatory bowel disease: a systematic review. J Crohns Colitis. 2020;14(2):254–66. https://doi.org/10.1093/ecco-jcc/jjz131.

    Article  PubMed  Google Scholar 

  20. Shiraishi K, Furukawa S, Yagi S, et al. Serum globulin is associated with endoscopic findings and mucosal healing in Japanese patients with ulcerative colitis. Dig Dis Sci. 2021. https://doi.org/10.1007/s10620-021-06834-5.

    Article  PubMed  Google Scholar 

  21. Shiraishi K, Furukawa S, Yagi S, et al. Association between serum bilirubin and mucosal healing among Japanese patients with ulcerative colitis: a cross-sectional study. Int J Colorectal Dis. 2021;36(2):377–82. https://doi.org/10.1007/s00384-020-03774-w.

    Article  PubMed  Google Scholar 

  22. Bertani L, Rossari F, Barberio B, et al. Novel prognostic biomarkers of mucosal healing in ulcerative colitis patients treated with anti-TNF: neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio. Inflamm Bowel Dis. 2020;26(10):1579–87. https://doi.org/10.1093/ibd/izaa062.

    Article  PubMed  Google Scholar 

  23. Akpinar MY, Ozin YO, Kaplan M, et al. Platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio predict mucosal disease severity in ulcerative colitis. J Med Biochem. 2018;37(2):155–62. https://doi.org/10.1515/jomb-2017-0050.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Eder P, Stawczyk-Eder K, Łykowska-Szuber L, et al. Association between disease duration and usefulness of fecal calprotectin measurement in patients with Crohn’s disease. Pol Arch Med Wewn. 2014;124(1–2):51–7.

    PubMed  Google Scholar 

  25. Ishida N, Miyazu T, Matsuura T, et al. Effect of ulcerative colitis duration on the usefulness of immunochemical fecal occult blood test result as a disease activity biomarker. Int J Colorectal Dis. 2020;35(9):1729–39. https://doi.org/10.1007/s00384-020-03636-5.

    Article  PubMed  Google Scholar 

  26. Yagi S, Furukawa S, Shiraishi K, et al. Effect of disease duration on the association between serum albumin and mucosal healing in patients with ulcerative colitis. BMJ Open Gastroenterol. 2021;8(1): e000662. https://doi.org/10.1136/bmjgast-2021-000662.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Chojkier M. Inhibition of albumin synthesis in chronic diseases: molecular mechanisms. J Clin Gastroenterol. 2005;39:S143–6. https://doi.org/10.1097/01.mcg.0000155514.17715.39.

    Article  CAS  PubMed  Google Scholar 

  28. Tominaga T, Nonaka T, Sumida Y, et al. The C-reactive protein to albumin ratio as a predictor of severe side effects of adjuvant chemotherapy in stage III colorectal cancer patients. PLoS ONE. 2016;11(12): e0167967. https://doi.org/10.1371/journal.pone.0167967.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Matsuoka T, Igarashi A, Sato N, et al. Trends in corticosteroid prescriptions for ulcerative colitis and factors associated with long-term corticosteroid use: analysis using Japanese claims data from 2006 to 2016. J Crohns Colitis. 2021;15(3):358–66. https://doi.org/10.1093/ecco-jcc/jjaa172.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Masakazu Hanayama, Keitarou Kawasaki, Yuji Mizukami, Satoshi Imamine, Masamoto Torisu, Harumi Yano, Makoto Yano, Masato Murakami, Masumi Hino, and Tomo Kogama.

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Health Services Center, Ehime University, Matsuyama, Ehime, 790-8577, Japan

    Shinya Furukawa

  2. Department of Internal Medicine, Saiseikai Matsuyama Hospital, Matsuyama, Ehime, 791-8026, Japan

    Sen Yagi & Hidehiro Murakami

  3. Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Ehime, 791-0295, Japan

    Kana Shiraishi, Teruki Miyake, Yu Hashimoto & Yoichi Hiasa

  4. Department of Inflammatory Bowel Diseases and Therapeutics, Ehime University Graduate School of Medicine, Toon, Ehime, 791-0295, Japan

    Kazuhiro Tange & Eiji Takeshita

  5. Department of Gastroenterology, Ehime Prefectural Central Hospital, Matsuyama, Ehime, 790-0024, Japan

    Shogo Kitahata, Tomoe Kawamura & Tomoyuki Ninomiya

  6. Department of Internal Medicine, Iyo Hospital, Iyo, Ehime, 799-3101, Japan

    Kenichirou Mori

  7. Department of Gastroenterology, Sumitomo Besshi Hospital, Niihama, Ehime, 792-8543, Japan

    Seiyuu Suzuki

  8. Department of Gastroenterology, Ehime Prefectural Niihama Hospital, Niihama, Ehime, 792-0042, Japan

    Naozumi Shibata

  9. Ohashi Clinic Participate in Gastro-Enterology and Ano-Proctology, Niihama, Ehime, 792-2856, Japan

    Katsuhisa Ohashi

  10. Department of Gastroenterology, Shikoku Cancer Center, Matsuyama, Ehime, 791-0280, Japan

    Aki Hasebe

  11. Endoscopy Center, Ehime University Hospital, Toon, Ehime, 791-0295, Japan

    Hideomi Tomida, Yasunori Yamamoto & Yoshio Ikeda

Authors
  1. Shinya Furukawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sen Yagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kana Shiraishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Teruki Miyake
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kazuhiro Tange
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yu Hashimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shogo Kitahata
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tomoe Kawamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tomoyuki Ninomiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kenichirou Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Seiyuu Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Naozumi Shibata
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Hidehiro Murakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Katsuhisa Ohashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Aki Hasebe
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Hideomi Tomida
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Yasunori Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Eiji Takeshita
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Yoshio Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Yoichi Hiasa
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conception and design: FS, SY, ET, YI, YoH; Material preparation and data collection: SF, SY, KS, TM, KT, YuH, SK, TK, TN, KM, SS, NS, HM, KO, AH, HT, YY, ET, YI; Data analysis: SF; Interpretation of data: SF, SY, ET, YI, and YoH; The first draft of the manuscript was written by SF; Supervision: YoH. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Shinya Furukawa.

Ethics declarations

Ethics approval and consent to participate

This study was conducted in accordance with the Declaration of Helsinki, and the study protocol was approved by the institutional review board of the Ehime University Graduate School of Medicine (#1505011). Trained staff obtained written informed consent from all enrolled patients.

Consent for publication

Not applicable.

Competing interests

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors declare that there is no conflict of interest regarding the publication of this article.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Furukawa, S., Yagi, S., Shiraishi, K. et al. Effect of disease duration on the association between C-reactive protein-albumin ratio and endoscopic activity in ulcerative colitis. BMC Gastroenterol 22, 39 (2022). https://doi.org/10.1186/s12876-022-02113-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12876-022-02113-3

Keywords

  • Mucosal healing
  • Ulcerative colitis
  • Clinical remission
  • Albumin
  • CRP/albumin ratio

BMC Gastroenterology

ISSN: 1471-230X

Contact us